Holen Sie sich die Stockscreener-App
120.33
0.46%
-0.54
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$120.87
Offen:
$120.41
24-Stunden-Volumen:
2.58M
Relative Volume:
0.22
Marktkapitalisierung:
$297.42B
Einnahmen:
$64.93B
Nettoeinkommen (Verlust:
$18.26B
KGV:
16.54
EPS:
7.2751
Netto-Cashflow:
$12.36B
1W Leistung:
+1.87%
1M Leistung:
+3.90%
6M Leistung:
+35.48%
1J Leistung:
+47.67%
1-Tages-Spanne:
$120.04
$121.48
1-Wochen-Bereich:
$118.77
$122.19
52-Wochen-Spanne:
$73.31
$125.14
Merck Co Inc Stock (MRK) Company Profile
Firmenname
Merck Co Inc
Sektor
Telefon
908-740-4000
Adresse
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
120.30 | 298.84B | 64.93B | 18.26B | 12.36B | 7.2751 |
LLY
Lilly Eli Co
|
920.29 | 835.81B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
240.83 | 585.39B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
205.33 | 369.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
203.47 | 315.58B | 58.80B | 10.24B | 8.98B | 3.2788 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-02-13 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2026-01-08 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-12-18 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-11-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-10-13 | Fortgesetzt | Citigroup | Neutral |
| 2025-09-17 | Herabstufung | Berenberg | Buy → Hold |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-02-18 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-02-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-01-08 | Herabstufung | Truist | Buy → Hold |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-12-04 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-11 | Herabstufung | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-03-11 | Herabstufung | Societe Generale | Hold → Sell |
| 2024-01-04 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-27 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Hold |
| 2023-04-13 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-03-28 | Herabstufung | Societe Generale | Buy → Hold |
| 2023-03-13 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | Eingeleitet | Jefferies | Buy |
| 2023-02-22 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-10 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-14 | Hochstufung | Berenberg | Hold → Buy |
| 2022-07-06 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | Fortgesetzt | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-16 | Eingeleitet | Daiwa Securities | Neutral |
| 2021-12-13 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-12-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-29 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-01 | Hochstufung | Argus | Hold → Buy |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-20 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-08-03 | Hochstufung | Goldman | Neutral → Buy |
| 2020-06-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-16 | Eingeleitet | SVB Leerink | Outperform |
| 2019-07-03 | Eingeleitet | Mizuho | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-05-13 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | Bestätigt | Citigroup | Buy |
| 2018-10-09 | Fortgesetzt | Guggenheim | Buy |
| 2018-04-23 | Hochstufung | Goldman | Neutral → Buy |
| 2018-04-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-03-12 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-07 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2018-01-16 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Merck Co Inc Aktie (MRK) Neueste Nachrichten
Merck & Co., Inc. $MRK Shares Sold by Rathbones Group PLC - MarketBeat
Merck & Co., Inc. $MRK Shares Bought by Quilter Plc - MarketBeat
JPMorgan Adjusts Price Target on Merck & Co. to $135 From $125, Maintains Overweight Rating - marketscreener.com
Leerink raises Merck & Co. Inc. (MRK) price target, sees upside from cancer drug - msn.com
Nvwm LLC Acquires 31,854 Shares of Merck & Co., Inc. $MRK - MarketBeat
JB Capital LLC Boosts Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Stock Position Trimmed by Florida Trust Wealth Management Co - MarketBeat
Merck & Co., Inc. (MRK) stock price, news, quote and history - Yahoo Finance UK
Perpetual Ltd Purchases 9,261 Shares of Merck & Co., Inc. $MRK - MarketBeat
SS&H Financial Advisors Inc. Acquires 12,200 Shares of Merck & Co., Inc. $MRK - MarketBeat
SteelPeak Wealth LLC Grows Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Purchased by Quintet Private Bank Europe S.A. - MarketBeat
Merck & Co., Inc. stock: Steady performer amid healthcare shifts - AD HOC NEWS
Erste Group Initiates Merck & Co(MRK.US) With Hold Rating - Moomoo
West Branch Capital LLC Sells 15,875 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. stock: Strong margins amid shifting pharma winds - ad-hoc-news.de
Eldred Rock Partners LLC Has $11.31 Million Stake in Merck & Co., Inc. $MRK - MarketBeat
10,200 Shares in Merck & Co., Inc. $MRK Purchased by FNY Investment Advisers LLC - MarketBeat
16,300 Shares in Merck & Co., Inc. $MRK Purchased by Dorato Capital Management - MarketBeat
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Grows Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Bought by Aberdeen Group plc - MarketBeat
Merck & Co., Inc. stock: A cornerstone of pharmaceutical innovation and dividend reliability for lon - AD HOC NEWS
FinancialContentMerck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer - markets.financialcontent.com
Merck Just Made a Big Bet on a New Cancer Growth Engine - Investing.com
Merck initiates Phase 2b/3 trial for treatment of age-related macular degeneration - ROI-NJ
Merck Announces Initiation of Pivotal Phase 2B/3 Trial Evaluating Mk-8748 for Treatment of Neovascular Age-Related Macular Degeneration - MarketScreener
Merck & Co Inc (MEX:MRK) Stock Price, Trades & News - GuruFocus
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investiga - PharmiWeb.com
Merck & Co. (MRK) Announces Detailed Results From the Phase 2 CADENCE Study - Insider Monkey
Merck's (MRK) Keytruda Gains Fast Track Status in Colorectal Can - gurufocus.com
Chongqing Zhifei Biological Products adjusts cooperation agreement with Merck & Co - MarketScreener
Merck wins EU nod for Keytruda combo in ovarian cancer (MRK) - Seeking Alpha
Merck (MRK) Gains EU Approval for Keytruda Regimen in Ovarian Ca - GuruFocus
Merck (MRK) Advances MK-8748 Trial for Eye Disease Treatment - GuruFocus
Merck Says EU Approves Keytruda Combination Regimen for Platinum-Resistant Ovarian Cancer - MarketScreener
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration - businesswire.com
Tema Etfs LLC Raises Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Purchased by Compagnie Lombard Odier SCmA - MarketBeat
Bank Pictet & Cie Europe AG Lowers Stake in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Banque Pictet & Cie SA - MarketBeat
Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9 - Insider Monkey
Startup Infinimmune sees close to $1 billion, validation in big Merck drug dealSan Francisco Business Times - The Business Journals
Merck (NYSE: MRK) director receives new cash-settled phantom stock grant - Stock Titan
Merck (MRK) director Glocer granted 405 phantom stock units, holds 5,100 shares - Stock Titan
Merck (NYSE: MRK) director granted new phantom stock units - Stock Titan
Merck & Co deal worth up to $838 million to Infinimmune - The Pharma Letter
What's Going On With Merck Stock Wednesday?Merck & Co (NYSE:MRK) - Benzinga
Vaughan Nelson Investment Management L.P. Sells 11,515 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Highline Wealth Partners LLC - MarketBeat
Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30 - businesswire.com
Nisa Investment Advisors LLC Increases Holdings in Merck & Co., Inc. $MRK - MarketBeat
Finanzdaten der Merck Co Inc-Aktie (MRK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):